Grünenthal Group
Zieglerstraße 6
52078 Aachen

Phone: +49 241 569-0

Contact Form

Adverse Drug Reaction Reporting



This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.

Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 20 percent of revenues in 2014.


Zalviso® receives positive CHMP opinion

Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients

The Grünenthal Group announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorization of sufentanil sublingual tablets for the management of acute moderate to severe post-operative pain in adult patients. The Zalviso® system, in-licensed from AcelRx Pharmaceuticals Inc., is an innovative drug-device combination for use in hospitals offering several safety features for patients. It utilizes the opioid agonist sufentanil formulated in a proprietary sublingual tablet and delivered through an easy to use pre-programmed, non-invasive administration device.
On an annual basis, there are 19 million surgical procedures with associated moderate to severe pain in the European Union. Management of acute post-operative pain remains a key challenge.